The 12-item psoriatic arthritis impact of disease questionnaire: Construct validity, reliability, and interpretability in a clinical setting

Journal of Rheumatology

Volumn 44, Issue 3, 2017, Pages 279-285

  Di Carlo, Marco ^a   Becciolini, Andrea ^b   Lato, Valentina ^a   Crotti, Chiara ^c   Favalli, Ennio Giulio ^b   Salaffi, Fausto ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Centro Trasfusionale e di Immunoematologia   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Patient reported outcomes; PsAID 12; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

12 ITEM PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE; ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS; CONSTRUCT VALIDITY; CONTROLLED STUDY; CONVERGENT VALIDITY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT-REPORTED OUTCOME; PSORIASIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RELIABILITY; SCORING SYSTEM; AGED; DISABILITY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

ADULT; AGED; ARTHRITIS, PSORIATIC; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

EID: 85016408567     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160924     Document Type: Article

References (26)

1. Frank L, Basch E, Selby JV; Patient-Centered Outcomes Research Institute. The PCORI perspective on patient-centered outcomes research. JAMA 2014;312:1513-4.
2. Brett J, Staniszewska S, Mockford C, Herron-Marx S, Hughes J, Tysall C, et al. A systematic review of the impact of patient and public involvement on service users, researchers and communities. Patient 2014;7:387-95.
3. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012-9.
4. de Wit MP, Kvien TK, Gossec L. Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: A case study from the field of rheumatology. RMD Open 2015;1:e000129.
5. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, et al. Finalisation and validation of the Rheumatoid Arthritis Impact of Disease score, a patient-derived composite measure of impact of rheumatoid arthritis: A EULAR initiative. Ann Rheum Dis 2011;70:935-42.
6. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060-71.
7. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale J D, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272-7.
8. Helliwell PS, Fitzgerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE Project). Ann Rheum Dis 2013;72:986-91.
9. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
10. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
11. Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int 2014;2014:528105.
12. FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 2012;71:358-62.
13. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-9.
14. Salaffi F, Di Carlo M, Carotti M, Farah S, Gutierrez M. The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag 2016;12:631-42.
15. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
16. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences study group. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:318-22.
17. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-63.
18. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10.
19. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91.
20. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369-75.
21. Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res 2013; 22:2489-99.
22. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
23. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811-8.
24. Machado PM. Measurements, composite scores and the art of 'cutting-off'. Ann Rheum Dis 2016;75:787-90.
25. Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatol Int 2014;34:1103-10.
26. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: A cross-sectional study. J Rheumatol 2016;43:1749-54.